Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
| Revenue (TTM) | $417.30M |
| Gross Profit (TTM) | $392.96M |
| EBITDA | $180.47M |
| Operating Margin | 46.10% |
| Return on Equity | 19.90% |
| Return on Assets | 9.04% |
| Revenue/Share (TTM) | $14.36 |
| Book Value | $43.37 |
| Price-to-Book | 7.74 |
| Price-to-Sales (TTM) | 24.85 |
| EV/Revenue | 21.73 |
| EV/EBITDA | 48.92 |
| Quarterly Earnings Growth (YoY) | 52.50% |
| Quarterly Revenue Growth (YoY) | 31.90% |
| Shares Outstanding | $29.48M |
| Float | $23.42M |
| % Insiders | 10.97% |
| % Institutions | 99.56% |
Volatility is currently expanding
Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology.
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KRYS and any ticker you trade — then tracks every position and per-strategy win rate.
